Click Here for 5% Off Your First Aladdin Purchase!
Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Recombinant Cytochrome P450 3A4/CYP3A4 Antibody - Primary antibody, specific to Cytochrome P450 3A4/CYP3A4, Rabbit IgG

  • ExactAb™
  • Recombinant
  • Validated
  • 0.18 mg/mL
Features and benefits
  • Short Overview:

    Recombinant; Rabbit anti Human Cytochrome P450 3A4/CYP3A4 Antibody; WB; Unconjugated

  • Species reactivity(Reacts with): Human
  • Isotype: Rabbit IgG
    Application:
  • WB
Item Number
Ab098736
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab098736-10μl
10μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$69.90
Ab098736-50μl
50μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$209.90
Ab098736-100μl
100μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$329.90
Ab098736-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,499.90
Add to Wish List Compare
Bulk Order  DATASHEET

Recombinant; Rabbit anti Human Cytochrome P450 3A4/CYP3A4 Antibody; WB; Unconjugated

View related series
Accession#:P08684 CYP3A4 Cytochrome P450 3A4 Gene ID:1576

Basic Description

Product NameRecombinant Cytochrome P450 3A4/CYP3A4 Antibody - Primary antibody, specific to Cytochrome P450 3A4/CYP3A4, Rabbit IgG
Synonyms1,8-cineole 2-exo-monooxygenase antibody | Albendazole monooxygenase antibody | Albendazole sulfoxidase antibody | CP33 antibody | CP34 antibody | CP3A4_HUMAN antibody | CYP3 antibody | CYP3A antibody | CYP3A3 antibody | CYP3A4 antibody | CYPIIIA3 antibod
Specifications & PurityExactAb™, Validated, Recombinant, 0.18 mg/mL
Host speciesRabbit
SpecificityCytochrome P450 3A4/CYP3A4
ImmunogenA synthetic peptide derived from human CYP3A4 (AA 450-503)
Positive ControlWB: Human fetal liver lysates.
ConjugationUnconjugated
GradeExactAb™, Recombinant, Validated
Product Description

Rabbit anti Human Cytochrome P450 3A4/CYP3A4 Antibody, Recombinant, could be used for WB and so on.
Application
WB: 1/500-1/1000
Protein Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. The enzyme also hydroxylates etoposide.

Product Properties

IsotypeRabbit IgG
Light Chain Typekappa
SDS-PAGE150 kDa
Purification MethodProtein A purified
FormLiquid
Concentration0.18 mg/mL
Storage TempStore at -20°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at 4℃ short term (1-2 weeks). Store at -20℃ long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

Recombinant Cytochrome P450 3A4/CYP3A4 Antibody (Ab098736)- Western Blot
Western blot analysis of Cytochrome P450 3A4 in Human fetal liver lysates using Recombinant Cytochrome P450 3A4/CYP3A4 Antibody (Ab098736) .


Associated Targets

CYP3A4 Tclin Cytochrome P450 3A4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Application

ApplicationDilution info
WB

1/500-1/1000

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

 SDS

 Specification Sheet

References

1. Song F, Lu S, Gunnet J, Xu JZ, Wines P, Proost J, Liang Y, Baumann C, Lenhard J, Murray WV et al..  (2007)  Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists..  J Med Chem,  50  (12): (2807-17).  [PMID:17500511]
2. Thoma G, Streiff MB, Kovarik J, Glickman F, Wagner T, Beerli C, Zerwes HG.  (2008)  Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo..  J Med Chem,  51  (24): (7915-20).  [PMID:19053768]
3. Ahmad S, Madsen CS, Stein PD, Janovitz E, Huang C, Ngu K, Bisaha S, Kennedy LJ, Chen BC, Zhao R et al..  (2008)  (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential..  J Med Chem,  51  (9): (2722-33).  [PMID:18412317]
4. Bolli MH, Marfurt J, Grisostomi C, Boss C, Binkert C, Hess P, Treiber A, Thorin E, Morrison K, Buchmann S et al..  (2004)  Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists..  J Med Chem,  47  (11): (2776-95).  [PMID:15139756]
5. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J et al..  (2008)  Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity..  J Med Chem,  51  (11): (3061-4).  [PMID:18447380]
6. Chowdhury S, Chafeev M, Liu S, Sun J, Raina V, Chui R, Young W, Kwan R, Fu J, Cadieux JA.  (2011)  Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain..  Bioorg Med Chem Lett,  21  (12): (3676-81).  [PMID:21570288]
7. Xia Y, Chackalamannil S, Greenlee WJ, Jayne C, Neustadt B, Stamford A, Vaccaro H, Xu XL, Baker H, O'Neill K et al..  (2011)  Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes..  Bioorg Med Chem Lett,  21  (11): (3290-6).  [PMID:21536438]
8. Scott JS, Birch AM, Brocklehurst KJ, Broo A, Brown HS, Butlin RJ, Clarke DS, Davidsson O, Ertan A, Goldberg K et al..  (2012)  Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation..  J Med Chem,  55  (11): (5361-79).  [PMID:22545772]
9. Morley AD, King S, Roberts B, Lever S, Teobald B, Fisher A, Cook T, Parker B, Wenlock M, Phillips C et al..  (2012)  Lead optimisation of pyrazoles as novel FPR1 antagonists..  Bioorg Med Chem Lett,  22  (1): (532-6).  [PMID:22094028]
10. Boatman PD, Lauring B, Schrader TO, Kasem M, Johnson BR, Skinner P, Jung JK, Xu J, Cherrier MC, Webb PJ et al..  (2012)  (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans..  J Med Chem,  55  (8): (3644-66).  [PMID:22435740]
11. Shen HC, Ding FX, Raghavan S, Deng Q, Luell S, Forrest MJ, Carballo-Jane E, Wilsie LC, Krsmanovic ML, Taggart AK et al..  (2010)  Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate..  J Med Chem,  53  (6): (2666-70).  [PMID:20184326]
12. Certal V, Halley F, Virone-Oddos A, Delorme C, Karlsson A, Rak A, Thompson F, Filoche-Rommé B, El-Ahmad Y, Carry JC et al..  (2012)  Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers..  J Med Chem,  55  (10): (4788-805).  [PMID:22524426]
13. McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands M, Ruddle R, Henley A, de Haven Brandon A, Valenti M et al..  (2010)  Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)..  J Med Chem,  53  (5): (2239-49).  [PMID:20151677]
14. Sheffler DJ, Wenthur CJ, Bruner JA, Carrington SJ, Vinson PN, Gogi KK, Blobaum AL, Morrison RD, Vamos M, Cosford ND et al..  (2012)  Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM..  Bioorg Med Chem Lett,  22  (12): (3921-5).  [PMID:22607673]
15. Jones CK, Engers DW, Thompson AD, Field JR, Blobaum AL, Lindsley SR, Zhou Y, Gogliotti RD, Jadhav S, Zamorano R et al..  (2011)  Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model..  J Med Chem,  54  (21): (7639-47).  [PMID:21966889]
16. Duplantier AJ, Efremov I, Candler J, Doran AC, Ganong AH, Haas JA, Hanks AN, Kraus KG, Lazzaro Jr JT, Lu J et al..  (2009)  3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization..  Bioorg Med Chem Lett,  19  (9): (2524-9).  [PMID:19328692]
17. Cid JM, Duvey G, Tresadern G, Nhem V, Furnari R, Cluzeau P, Vega JA, de Lucas AI, Matesanz E, Alonso JM et al..  (2012)  Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor..  J Med Chem,  55  (5): (2388-405).  [PMID:22364337]
18. Cui JJ, McTigue M, Nambu M, Tran-Dubé M, Pairish M, Shen H, Jia L, Cheng H, Hoffman J, Le P et al..  (2012)  Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer..  J Med Chem,  55  (18): (8091-109).  [PMID:22924734]
19. Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, Doty JL, Elliott EA, Fisher MB, Hines M et al..  (2010)  Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection..  J Med Chem,  53  (24): (8468-84).  [PMID:21105711]
20. Evans KA, Budzik BW, Ross SA, Wisnoski DD, Jin J, Rivero RA, Vimal M, Szewczyk GR, Jayawickreme C, Moncol DL et al..  (2009)  Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists..  J Med Chem,  52  (24): (7962-5).  [PMID:19902954]
21. Nagase T, Mizutani T, Ishikawa S, Sekino E, Sasaki T, Fujimura T, Ito S, Mitobe Y, Miyamoto Y, Yoshimoto R et al..  (2008)  Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists..  J Med Chem,  51  (15): (4780-9).  [PMID:18598020]
22. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A et al..  (2011)  Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder..  J Med Chem,  54  (9): (3206-21).  [PMID:21486038]
23. Huynh T, Chen Z, Pang S, Geng J, Bandiera T, Bindi S, Vianello P, Roletto F, Thieffine S, Galvani A et al..  (2009)  Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)..  Bioorg Med Chem Lett,  19  (11): (2924-7).  [PMID:19419866]
24. Pinard E, Alanine A, Alberati D, Bender M, Borroni E, Bourdeaux P, Brom V, Burner S, Fischer H, Hainzl D et al..  (2010)  Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia..  J Med Chem,  53  (12): (4603-14).  [PMID:20491477]
25. Cumming JG, Tucker H, Oldfield J, Fielding C, Highton A, Faull A, Wild M, Brown D, Wells S, Shaw J.  (2012)  Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis..  Bioorg Med Chem Lett,  22  (4): (1655-9).  [PMID:22266038]
26. Breslin HJ, Diamond CJ, Kavash RW, Cai C, Dyatkin AB, Miskowski TA, Zhang SP, Wade PR, Hornby PJ, He W.  (2012)  Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)..  Bioorg Med Chem Lett,  22  (14): (4869-72).  [PMID:22695132]
27. Scott JS, Bowker SS, Deschoolmeester J, Gerhardt S, Hargreaves D, Kilgour E, Lloyd A, Mayers RM, McCoull W, Newcombe NJ et al..  (2012)  Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017)..  J Med Chem,  55  (12): (5951-64).  [PMID:22691057]
28. William AD, Lee AC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Tan E, Chen D, Williams M, Sun ET et al..  (2011)  Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma..  J Med Chem,  54  (13): (4638-58).  [PMID:21604762]
29. Birch AM, Birtles S, Buckett LK, Kemmitt PD, Smith GJ, Smith TJ, Turnbull AV, Wang SJ.  (2009)  Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor..  J Med Chem,  52  (6): (1558-68).  [PMID:19256504]
30. Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, Patel VK, Smee PA, Somers DO, Vitulli G et al..  (2009)  p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression..  J Med Chem,  52  (20): (6257-69).  [PMID:19772287]
31. Liu C, Lin J, Wrobleski ST, Lin S, Hynes J, Wu H, Dyckman AJ, Li T, Wityak J, Gillooly KM et al..  (2010)  Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases..  J Med Chem,  53  (18): (6629-39).  [PMID:20804198]
32. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H et al..  (2011)  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase..  J Med Chem,  54  (20): (7066-83).  [PMID:21936542]
33. Ruf S, Buning C, Schreuder H, Horstick G, Linz W, Olpp T, Pernerstorfer J, Hiss K, Kroll K, Kannt A et al..  (2012)  Novel β-amino acid derivatives as inhibitors of cathepsin A..  J Med Chem,  55  (17): (7636-49).  [PMID:22861813]
34. Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L et al..  (2012)  Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E..  J Med Chem,  55  (3): (1082-105).  [PMID:22168626]
35. Agarwal V, Kommaddi RP, Valli K, Ryder D, Hyde TM, Kleinman JE, Strobel HW, Ravindranath V.  (2008)  Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite..  PLoS ONE,  3  (6): (e2337).  [PMID:18545703]
36. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, Jhoti H.  (2004)  Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone..  Science,  305  (5684): (683-6).  [PMID:15256616]
37. Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, Mortimore M, O'Donnell ME, Pinder JL, Reaper PM et al..  (2011)  Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents..  J Med Chem,  54  (7): (2320-30).  [PMID:21413798]
38. Hanan EJ, van Abbema A, Barrett K, Blair WS, Blaney J, Chang C, Eigenbrot C, Flynn S, Gibbons P, Hurley CA et al..  (2012)  Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors..  J Med Chem,  55  (22): (10090-107).  [PMID:23061660]
39. Millan DS, Bunnage ME, Burrows JL, Butcher KJ, Dodd PG, Evans TJ, Fairman DA, Hughes SJ, Kilty IC, Lemaitre A et al..  (2011)  Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease..  J Med Chem,  54  (22): (7797-814).  [PMID:21888439]
40. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K et al..  (2012)  Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent..  J Med Chem,  55  (2): (903-13).  [PMID:22148921]
41. Fang X, Yin Y, Chen YT, Yao L, Wang B, Cameron MD, Lin L, Khan S, Ruiz C, Schröter T et al..  (2010)  Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors..  J Med Chem,  53  (15): (5727-37).  [PMID:20684608]
42. Pan Y, Gerasimov MR, Kvist T, Wellendorph P, Madsen KK, Pera E, Lee H, Schousboe A, Chebib M, Bräuner-Osborne H et al..  (2012)  (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction..  J Med Chem,  55  (1): (357-66).  [PMID:22128851]
43. Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA et al..  (2010)  Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase..  J Med Chem,  53  (10): (3973-4001).  [PMID:20420387]
44. Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A, Wen J, Chen T, Huang CQ, Chen M et al..  (2008)  Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor..  J Med Chem,  51  (23): (7478-85).  [PMID:19006286]
45. De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J et al..  (2011)  Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis..  Bioorg Med Chem Lett,  21  (11): (3301-6).  [PMID:21536437]
46. Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, Müller-Vieira U, Lauterbach T, Hartmann RW.  (2008)  Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer..  J Med Chem,  51  (16): (5009-18).  [PMID:18672868]
47. Vachal P, Miao S, Pierce JM, Guiadeen D, Colandrea VJ, Wyvratt MJ, Salowe SP, Sonatore LM, Milligan JA, Hajdu R et al..  (2012)  1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia..  J Med Chem,  55  (7): (2945-59).  [PMID:22364528]
48. Boezio AA, Berry L, Albrecht BK, Bauer D, Bellon SF, Bode C, Chen A, Choquette D, Dussault I, Fang M et al..  (2009)  Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors..  Bioorg Med Chem Lett,  19  (22): (6307-12).  [PMID:19819693]
49. Duplantier AJ, Dombroski MA, Subramanyam C, Beaulieu AM, Chang SP, Gabel CA, Jordan C, Kalgutkar AS, Kraus KG, Labasi JM et al..  (2011)  Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535..  Bioorg Med Chem Lett,  21  (12): (3708-11).  [PMID:21565499]
50. William AD, Lee AC, Goh KC, Blanchard S, Poulsen A, Teo EL, Nagaraj H, Lee CP, Wang H, Williams M et al..  (2012)  Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer..  J Med Chem,  55  (1): (169-96).  [PMID:22148278]
51. Xiong Y, Guo J, Candelore MR, Liang R, Miller C, Dallas-Yang Q, Jiang G, McCann PE, Qureshi SA, Tong X et al..  (2012)  Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes..  J Med Chem,  55  (13): (6137-48).  [PMID:22708876]
52. Miwatashi S, Arikawa Y, Kotani E, Miyamoto M, Naruo K, Kimura H, Tanaka T, Asahi S, Ohkawa S.  (2005)  Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent..  J Med Chem,  48  (19): (5966-79).  [PMID:16162000]
53. Kamenecka T, Jiang R, Song X, Duckett D, Chen W, Ling YY, Habel J, Laughlin JD, Chambers J, Figuera-Losada M et al..  (2010)  Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors..  J Med Chem,  53  (1): (419-31).  [PMID:19947601]
54. Dugan BJ, Gingrich DE, Mesaros EF, Milkiewicz KL, Curry MA, Zulli AL, Dobrzanski P, Serdikoff C, Jan M, Angeles TS et al..  (2012)  A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779..  J Med Chem,  55  (11): (5243-54).  [PMID:22594690]
55. Ohtake Y, Sato T, Kobayashi T, Nishimoto M, Taka N, Takano K, Yamamoto K, Ohmori M, Yamaguchi M, Takami K et al..  (2012)  Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes..  J Med Chem,  55  (17): (7828-40).  [PMID:22889351]
56. Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F, O'Connor R et al..  (2009)  Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia..  J Med Chem,  52  (16): (5188-96).  [PMID:19630403]
57. Goldstein DM, Soth M, Gabriel T, Dewdney N, Kuglstatter A, Arzeno H, Chen J, Bingenheimer W, Dalrymple SA, Dunn J et al..  (2011)  Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase..  J Med Chem,  54  (7): (2255-65).  [PMID:21375264]
58. Gaggini F, Laleu B, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F et al..  (2011)  Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors..  Bioorg Med Chem,  19  (23): (6989-99).  [PMID:22041175]
59. Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F et al..  (2010)  First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis..  J Med Chem,  53  (21): (7715-30).  [PMID:20942471]
60. Moore WJ, Kern JC, Bhat R, Commons TJ, Fukayama S, Goljer I, Krishnamurthy G, Magolda RL, Nogle L, Pitts K et al..  (2009)  Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides..  J Med Chem,  52  (1): (105-16).  [PMID:19072540]
61. Makoto Matsumoto,Hiroyuki Hashizume,Tatsuo Tomishige,Masanori Kawasaki,Hidetsugu Tsubouchi,Hirofumi Sasaki,Yoshihiko Shimokawa,Makoto Komatsu.  (2006-11-30)  OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice..  PLoS medicine,  3  ((11)): (e466-e466).  [PMID:17132069]
62. Denise C Endringer,Keller G Guimarães,Tamara P Kondratyuk,John M Pezzuto,Fernão C Braga.  (2008-05-09)  Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara..  Journal of natural products,  71  ((6)): (1082-1084).  [PMID:18462007]
63. Derek C Cole,Joseph R Stock,Anthony F Kreft,Madelene Antane,Suzan H Aschmies,Kevin P Atchison,David S Casebier,Thomas A Comery,George Diamantidis,John W Ellingboe,Boyd L Harrison,Yun Hu,Mei Jin,Dennis M Kubrak,Peimin Lu,Charles W Mann,Robert L Martone,William J Moore,Aram Oganesian,David R Riddell,June Sonnenberg-Reines,Shaiu-Ching Sun,Erik Wagner,Zheng Wang,Kevin R Woller,Zheng Xu,Hua Zhou,J Steven Jacobsen.  (2008-12-23)  (S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor..  Bioorganic & medicinal chemistry letters,  19  ((3)): (926-929).  [PMID:19097890]
64. Christoph Gibson, Karsten Schnatbaum, Jochen R Pfeifer, Elsa Locardi, Matthias Paschke, Ulf Reimer, Uwe Richter, Dirk Scharn, Alexander Faussner, Thomas Tradler,.  (2009-06-26)  Novel small molecule bradykinin B2 receptor antagonists..  Journal of medicinal chemistry,  52  ((14)): ( 4370-4379 ).  [PMID:19552431]
65. Stuart N L Bennett,Andrew D Campbell,Andrew Hancock,Craig Johnstone,Peter W Kenny,Adrian Pickup,Alleyn T Plowright,Nidhal Selmi,Iain Simpson,Andy Stocker,David P Whalley,Paul R O Whittamore.  (2010-05-25)  Discovery of a series of indan carboxylic acid glycogen phosphorylase inhibitors..  Bioorganic & medicinal chemistry letters,  20  ((12)): (3511-3514).  [PMID:20493691]
66. Qingzhong Hu,Carsten Jagusch,Ulrike E Hille,Jörg Haupenthal,Rolf W Hartmann.  (2010-08-06)  Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer..  Journal of medicinal chemistry,  53  ((15)): (5749-5758).  [PMID:20684610]
67. Jill M Scott,Christopher Baccei,Gretchen Bain,Alex Broadhead,Jilly F Evans,Patrick Fagan,John H Hutchinson,Christopher King,Daniel S Lorrain,Catherine Lee,Peppi Prasit,Pat Prodanovich,Angelina Santini,Brian A Stearns.  (2011-10-01)  Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis..  Bioorganic & medicinal chemistry letters,  21  ((21)): (6608-6612).  [PMID:21958540]
68. Weiguo Liu,Fiona Lau,Kun Liu,Harold B Wood,Gaochao Zhou,Yuli Chen,Ying Li,Taro E Akiyama,Gino Castriota,Monica Einstein,Chualin Wang,Margaret E McCann,Thomas W Doebber,Margaret Wu,Ching H Chang,Lesley McNamara,Brian McKeever,Ralph T Mosley,Joel P Berger,Peter T Meinke.  (2011-11-11)  Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators..  Journal of medicinal chemistry,  54  ((24)): (8541-8554).  [PMID:22070604]
69. Chi-Chi Peng,Wei Shi,Justin D Lutz,Kent L Kunze,Jun O Liu,Wendel L Nelson,Nina Isoherranen.  (2011-11-23)  Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals..  Drug metabolism and disposition: the biological fate of chemicals,  40  ((3)): (426-435).  [PMID:22106171]
70. Raman Sharma,Hao Sun,David W Piotrowski,Tim F Ryder,Shawn D Doran,Haiqing Dai,Chandra Prakash.  (2012-08-17)  Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human..  Drug metabolism and disposition: the biological fate of chemicals,  40  ((11)): (2143-2161).  [PMID:22896728]
71. Marieke Voets,Iris Antes,Christiane Scherer,Ursula Müller-Vieira,Klaus Biemel,Catherine Barassin,Sandrine Marchais-Oberwinkler,Rolf W Hartmann.  (2005-10-14)  Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis..  Journal of medicinal chemistry,  48  ((21)): (6632-6642).  [PMID:16220979]
72. Thomas Lübbers,Markus Böhringer,Luca Gobbi,Michael Hennig,Daniel Hunziker,Bernd Kuhn,Bernd Löffler,Patrizio Mattei,Robert Narquizian,Jens-Uwe Peters,Yves Ruff,Hans Peter Wessel,Pierre Wyss.  (2007-04-10)  1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors..  Bioorganic & medicinal chemistry letters,  17  ((11)): (2966-2970).  [PMID:17418568]
73. Ralf Heim,Simon Lucas,Cornelia M Grombein,Christina Ries,Katarzyna E Schewe,Matthias Negri,Ursula Müller-Vieira,Barbara Birk,Rolf W Hartmann.  (2008-08-05)  Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity..  Journal of medicinal chemistry,  51  ((16)): (5064-5074).  [PMID:18672861]
74. Qingzhong Hu,Matthias Negri,Kerstin Jahn-Hoffmann,Yan Zhuang,Sureyya Olgen,Marc Bartels,Ursula Müller-Vieira,Thomas Lauterbach,Rolf W Hartmann.  (2008-08-05)  Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge..  Bioorganic & medicinal chemistry,  16  ((16)): (7715-7727).  [PMID:18674917]
75. Paul A Brough,Xavier Barril,Jenifer Borgognoni,Patrick Chene,Nicholas G M Davies,Ben Davis,Martin J Drysdale,Brian Dymock,Suzanne A Eccles,Carlos Garcia-Echeverria,Christophe Fromont,Angela Hayes,Roderick E Hubbard,Allan M Jordan,Michael Rugaard Jensen,Andrew Massey,Angela Merrett,Antony Padfield,Rachel Parsons,Thomas Radimerski,Florence I Raynaud,Alan Robertson,Stephen D Roughley,Joseph Schoepfer,Heather Simmonite,Swee Y Sharp,Allan Surgenor,Melanie Valenti,Steven Walls,Paul Webb,Mike Wood,Paul Workman,Lisa Wright.  (2009-07-21)  Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone..  Journal of medicinal chemistry,  52  ((15)): (4794-4809).  [PMID:19610616]
76. Guangxin Xia,Mengzhu Xue,Lin Liu,Jianxin Yu,Haiyan Liu,Ping Li,Jianfa Wang,Yanlian Li,Bing Xiong,Jingkang Shen.  (2011-08-30)  Potent and novel 11β-HSD1 inhibitors identified from shape and docking based virtual screening..  Bioorganic & medicinal chemistry letters,  21  ((19)): (5739-5744).  [PMID:21873057]
77. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G..  (2004)  Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis..  Bioorg Med Chem Lett,  14  (13): (3595-3599).  [PMID:15177482]
78. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G..  (2004)  SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity..  Bioorg Med Chem Lett,  14  (13): (3601-3605).  [PMID:15177483]
79. Bell IM, Gallicchio SN, Abrams M, Beese LS, Beshore DC, Bhimnathwala H, Bogusky MJ, Buser CA, Culberson JC, Davide J, Ellis-Hutchings M, Fernandes C, Gibbs JB, Graham SL, Hamilton KA, Hartman GD, Heimbrook DC, Homnick CF, Huber HE, Huff JR, Kassahun K, Koblan KS, Kohl NE, Lobell RB, Lynch JJ, Robinson R, Rodrigues AD, Taylor JS, Walsh ES, Williams TM, Zartman CB..  (2002)  3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency..  J Med Chem,  45  (12): (2388-2409).  [PMID:12036349]
80. Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Fura A, Kamath A, Vyas V, Tokarski JS, Barrish JC, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS..  (2005)  Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors..  J Med Chem,  48  (12): (3991-4008).  [PMID:15943473]
81. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG..  (2005)  Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes..  J Med Chem,  48  (15): (5025-5037).  [PMID:16033281]
82. de Dios A, Shih C, López de Uralde B, Sánchez C, del Prado M, Martín Cabrejas LM, Pleite S, Blanco-Urgoiti J, Lorite MJ, Nevill CR, Bonjouklian R, York J, Vieth M, Wang Y, Magnus N, Campbell RM, Anderson BD, McCann DJ, Giera DD, Lee PA, Schultz RM, Li LC, Johnson LM, Wolos JA..  (2005)  Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy..  J Med Chem,  48  (7): (2270-2273).  [PMID:15801819]
83. Voets M, Antes I, Scherer C, Müller-Vieira U, Biemel K, Marchais-Oberwinkler S, Hartmann RW..  (2006)  Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis..  J Med Chem,  49  (7): (2222-2231).  [PMID:16570918]
84. Young WB, Mordenti J, Torkelson S, Shrader WD, Kolesnikov A, Rai R, Liu L, Hu H, Leahy EM, Green MJ, Sprengeler PA, Katz BA, Yu C, Janc JW, Elrod KC, Marzec UM, Hanson SR..  (2006)  Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model..  Bioorg Med Chem Lett,  16  (7): (2037-2041).  [PMID:16412633]
85. Ghosh S, Elder A, Guo J, Mani U, Patane M, Carson K, Ye Q, Bennett R, Chi S, Jenkins T, Guan B, Kolbeck R, Smith S, Zhang C, LaRosa G, Jaffee B, Yang H, Eddy P, Lu C, Uttamsingh V, Horlick R, Harriman G, Flynn D..  (2006)  Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8)..  J Med Chem,  49  (9): (2669-2672).  [PMID:16640325]
86. Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S..  (2006)  An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression..  J Med Chem,  49  (11): (3116-3135).  [PMID:16722631]
87. Madar DJ, Kopecka H, Pireh D, Yong H, Pei Z, Li X, Wiedeman PE, Djuric SW, Von Geldern TW, Fickes MG, Bhagavatula L, McDermott T, Wittenberger S, Richards SJ, Longenecker KL, Stewart KD, Lubben TH, Ballaron SJ, Stashko MA, Long MA, Wells H, Zinker BA, Mika AK, Beno DW, Kempf-Grote AJ, Polakowski J, Segreti J, Reinhart GA, Fryer RM, Sham HL, Trevillyan JM..  (2006)  Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes..  J Med Chem,  49  (21): (6416-6420).  [PMID:17034148]
88. Pei Z, Li X, von Geldern TW, Madar DJ, Longenecker K, Yong H, Lubben TH, Stewart KD, Zinker BA, Backes BJ, Judd AS, Mulhern M, Ballaron SJ, Stashko MA, Mika AK, Beno DW, Reinhart GA, Fryer RM, Preusser LC, Kempf-Grote AJ, Sham HL, Trevillyan JM..  (2006)  Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes..  J Med Chem,  49  (22): (6439-6442).  [PMID:17064063]
89. Kaila N, Janz K, DeBernardo S, Bedard PW, Camphausen RT, Tam S, Tsao DH, Keith JC, Nickerson-Nutter C, Shilling A, Young-Sciame R, Wang Q..  (2007)  Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists..  J Med Chem,  50  (1): (21-39).  [PMID:17201408]
90. Liverton NJ, Bednar RA, Bednar B, Butcher JW, Claiborne CF, Claremon DA, Cunningham M, DiLella AG, Gaul SL, Libby BE, Lyle EA, Lynch JJ, McCauley JA, Mosser SD, Nguyen KT, Stump GL, Sun H, Wang H, Yergey J, Koblan KS..  (2007)  Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist..  J Med Chem,  50  (4): (807-819).  [PMID:17249648]
91. Rudolph J, Chen L, Majumdar D, Bullock WH, Burns M, Claus T, Dela Cruz FE, Daly M, Ehrgott FJ, Johnson JS, Livingston JN, Schoenleber RW, Shapiro J, Yang L, Tsutsumi M, Ma X..  (2007)  Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy..  J Med Chem,  50  (5): (984-1000).  [PMID:17274610]
92. Wacker DA, Varnes JG, Malmstrom SE, Cao X, Hung CP, Ung T, Wu G, Zhang G, Zuvich E, Thomas MA, Keim WJ, Cullen MJ, Rohrbach KW, Qu Q, Narayanan R, Rossi K, Janovitz E, Lehman-McKeeman L, Malley MF, Devenny J, Pelleymounter MA, Miller KJ, Robl JA..  (2007)  Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor..  J Med Chem,  50  (6): (1365-1379).  [PMID:17315987]
93. Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, Gwaltney SL..  (2007)  Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV..  J Med Chem,  50  (10): (2297-2300).  [PMID:17441705]
94. Garzya V, Forbes IT, Gribble AD, Hadley MS, Lightfoot AP, Payne AH, Smith AB, Douglas SE, Cooper DG, Stansfield IG, Meeson M, Dodds EE, Jones DN, Wood M, Reavill C, Scorer CA, Worby A, Riley G, Eddershaw P, Ioannou C, Donati D, Hagan JJ, Ratti EA..  (2007)  Studies towards the identification of a new generation of atypical antipsychotic agents..  Bioorg Med Chem Lett,  17  (2): (400-405).  [PMID:17084080]
95. Wilson DP, Wan ZK, Xu WX, Kirincich SJ, Follows BC, Joseph-McCarthy D, Foreman K, Moretto A, Wu J, Zhu M, Binnun E, Zhang YL, Tam M, Erbe DV, Tobin J, Xu X, Leung L, Shilling A, Tam SY, Mansour TS, Lee J..  (2007)  Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site..  J Med Chem,  50  (19): (4681-4698).  [PMID:17705360]
96. Green N, Hu Y, Janz K, Li HQ, Kaila N, Guler S, Thomason J, Joseph-McCarthy D, Tam SY, Hotchandani R, Wu J, Huang A, Wang Q, Leung L, Pelker J, Marusic S, Hsu S, Telliez JB, Hall JP, Cuozzo JW, Lin LL..  (2007)  Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles..  J Med Chem,  50  (19): (4728-4745).  [PMID:17715908]
97. Reck F, Zhou F, Eyermann CJ, Kern G, Carcanague D, Ioannidis G, Illingworth R, Poon G, Gravestock MB..  (2007)  Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility..  J Med Chem,  50  (20): (4868-4881).  [PMID:17722903]
98. Jiang W, Tucci FC, Tran JA, Fleck BA, Wen J, Markison S, Marinkovic D, Chen CW, Arellano M, Hoare SR, Johns M, Foster AC, Saunders J, Chen C..  (2007)  Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor..  Bioorg Med Chem Lett,  17  (20): (5610-5613).  [PMID:17822895]
99. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M..  (2007)  Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice..  J Med Chem,  50  (23): (5579-5588).  [PMID:17929792]
100. Backes BJ, Longenecker K, Hamilton GL, Stewart K, Lai C, Kopecka H, von Geldern TW, Madar DJ, Pei Z, Lubben TH, Zinker BA, Tian Z, Ballaron SJ, Stashko MA, Mika AK, Beno DW, Kempf-Grote AJ, Black-Schaefer C, Sham HL, Trevillyan JM..  (2007)  Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit..  Bioorg Med Chem Lett,  17  (7): (2005-2012).  [PMID:17276063]
101. Feng Y, Cameron MD, Frackowiak B, Griffin E, Lin L, Ruiz C, Schröter T, LoGrasso P..  (2007)  Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II..  Bioorg Med Chem Lett,  17  (8): (2355-2360).  [PMID:17368019]
102. Thurmond J, Butchbach ME, Palomo M, Pease B, Rao M, Bedell L, Keyvan M, Pai G, Mishra R, Haraldsson M, Andresson T, Bragason G, Thosteinsdottir M, Bjornsson JM, Coovert DD, Burghes AH, Gurney ME, Singh J..  (2008)  Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy..  J Med Chem,  51  (3): (449-469).  [PMID:18205293]
103. McBriar MD, Clader JW, Chu I, Del Vecchio RA, Favreau L, Greenlee WJ, Hyde LA, Nomeir AA, Parker EM, Pissarnitski DA, Song L, Zhang L, Zhao Z..  (2008)  Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors..  Bioorg Med Chem Lett,  18  (1): (215-219).  [PMID:17988864]
104. Zhang X, Rueter JK, Chen Y, Moorjani M, Lanier MC, Lin E, Gross RS, Tellew JE, Williams JP, Lechner SM, Markison S, Joswig T, Malany S, Santos M, Castro-Palomino JC, Crespo MI, Prat M, Gual S, Díaz JL, Saunders J, Slee DH..  (2008)  Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists..  Bioorg Med Chem Lett,  18  (6): (1778-1783).  [PMID:18329269]
105. Wang W, Devasthale P, Farrelly D, Gu L, Harrity T, Cap M, Chu C, Kunselman L, Morgan N, Ponticiello R, Zebo R, Zhang L, Locke K, Lippy J, O'Malley K, Hosagrahara V, Zhang L, Kadiyala P, Chang C, Muckelbauer J, Doweyko AM, Zahler R, Ryono D, Hariharan N, Cheng PT..  (2008)  Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists..  Bioorg Med Chem Lett,  18  (6): (1939-1944).  [PMID:18291645]
106. Frotscher M, Ziegler E, Marchais-Oberwinkler S, Kruchten P, Neugebauer A, Fetzer L, Scherer C, Müller-Vieira U, Messinger J, Thole H, Hartmann RW..  (2008)  Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases..  J Med Chem,  51  (7): (2158-2169).  [PMID:18324762]
107. Cai ZW, Wei D, Borzilleri RM, Qian L, Kamath A, Mortillo S, Wautlet B, Henley BJ, Jeyaseelan R, Tokarski J, Hunt JT, Bhide RS, Fargnoli J, Lombardo LJ..  (2008)  Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors..  Bioorg Med Chem Lett,  18  (4): (1354-1358).  [PMID:18221875]
108. Crosignani S, Page P, Missotten M, Colovray V, Cleva C, Arrighi JF, Atherall J, Macritchie J, Martin T, Humbert Y, Gaudet M, Pupowicz D, Maio M, Pittet PA, Golzio L, Giachetti C, Rocha C, Bernardinelli G, Filinchuk Y, Scheer A, Schwarz MK, Chollet A..  (2008)  Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases..  J Med Chem,  51  (7): (2227-2243).  [PMID:18318469]
109. Wustrow DJ, Maynard GD, Yuan J, Zhao H, Mao J, Guo Q, Kershaw M, Hammer J, Brodbeck RM, Near KE, Zhou D, Beers DS, Chenard BL, Krause JE, Hutchison AJ..  (2008)  Aminopyrazine CB1 receptor inverse agonists..  Bioorg Med Chem Lett,  18  (11): (3376-3381).  [PMID:18448340]
110. Imaeda Y, Kuroita T, Sakamoto H, Kawamoto T, Tobisu M, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K..  (2008)  Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors..  J Med Chem,  51  (12): (3422-3436).  [PMID:18507371]
111. Isin EM, Guengerich FP..  (2007)  Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4..  J Biol Chem,  282  (9): (6863-6874).  [PMID:17200113]
112. Angell R, Aston NM, Bamborough P, Buckton JB, Cockerill S, deBoeck SJ, Edwards CD, Holmes DS, Jones KL, Laine DI, Patel S, Smee PA, Smith KJ, Somers DO, Walker AL..  (2008)  Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity..  Bioorg Med Chem Lett,  18  (15): (4428-4432).  [PMID:18614366]
113. Akwabi-Ameyaw A, Bass JY, Caldwell RD, Caravella JA, Chen L, Creech KL, Deaton DN, Jones SA, Kaldor I, Liu Y, Madauss KP, Marr HB, McFadyen RB, Miller AB, Navas F, Parks DJ, Spearing PK, Todd D, Williams SP, Wisely GB..  (2008)  Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064..  Bioorg Med Chem Lett,  18  (15): (4339-4343).  [PMID:18621523]
114. Ohnmacht S, Nava P, West R, Parker R, Atkinson J..  (2008)  Inhibition of oxidative metabolism of tocopherols with omega-N-heterocyclic derivatives of vitamin E..  Bioorg Med Chem,  16  (16): (7631-7638).  [PMID:18656365]
115. Degnan AP, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Denton R, Han X, Macci R, Mathias NR, Moench P, Pin SS, Ren SX, Schartman R, Signor LJ, Thalody G, Widmann KA, Xu C, Macor JE, Dubowchik GM..  (2008)  Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure..  J Med Chem,  51  (16): (4858-4861).  [PMID:18665579]
116. Kim RM, Chang J, Lins AR, Brady E, Candelore MR, Dallas-Yang Q, Ding V, Dragovic J, Iliff S, Jiang G, Mock S, Qureshi S, Saperstein R, Szalkowski D, Tamvakopoulos C, Tota L, Wright M, Yang X, Tata JR, Chapman K, Zhang BB, Parmee ER..  (2008)  Discovery of potent, orally active benzimidazole glucagon receptor antagonists..  Bioorg Med Chem Lett,  18  (13): (3701-3705).  [PMID:18539028]
117. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P..  (2008)  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors..  J Med Chem,  51  (21): (6642-6645).  [PMID:18834107]
118. Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, Kruchten P, Oster A, Frotscher M, Birk B, Hartmann RW..  (2008)  Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1)..  J Med Chem,  51  (21): (6725-6739).  [PMID:18855374]
119. Gopalsamy A, Shi M, Stauffer B, Bahat R, Billiard J, Ponce-de-Leon H, Seestaller-Wehr L, Fukayama S, Mangine A, Moran R, Krishnamurthy G, Bodine P..  (2008)  Identification of diarylsulfone sulfonamides as secreted frizzled related protein-1 (sFRP-1) inhibitors..  J Med Chem,  51  (24): (7670-7672).  [PMID:19053830]
120. Jones CD, Andrews DM, Barker AJ, Blades K, Daunt P, East S, Geh C, Graham MA, Johnson KM, Loddick SA, McFarland HM, McGregor A, Moss L, Rudge DA, Simpson PB, Swain ML, Tam KY, Tucker JA, Walker M..  (2008)  The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing..  Bioorg Med Chem Lett,  18  (24): (6369-6373).  [PMID:18996007]
121. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, Klinghofer V, Johnson EF, Donawho CK, Frost DJ, Bontcheva-Diaz V, Bouska JJ, Osterling DJ, Olson AM, Marsh KC, Luo Y, Giranda VL..  (2009)  Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer..  J Med Chem,  52  (2): (514-523).  [PMID:19143569]
122. Pettus LH, Xu S, Cao GQ, Chakrabarti PP, Rzasa RM, Sham K, Wurz RP, Zhang D, Middleton S, Henkle B, Plant MH, Saris CJ, Sherman L, Wong LM, Powers DA, Tudor Y, Yu V, Lee MR, Syed R, Hsieh F, Tasker AS..  (2008)  3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase..  J Med Chem,  51  (20): (6280-6292).  [PMID:18817364]
123. Vu CB, Bemis JE, Disch JS, Ng PY, Nunes JJ, Milne JC, Carney DP, Lynch AV, Smith JJ, Lavu S, Lambert PD, Gagne DJ, Jirousek MR, Schenk S, Olefsky JM, Perni RB..  (2009)  Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators..  J Med Chem,  52  (5): (1275-1283).  [PMID:19199480]
124. Gilbert AM, Bursavich MG, Lombardi S, Georgiadis KE, Reifenberg E, Flannery CR, Morris EA..  (2008)  N-((8-hydroxy-5-substituted-quinolin-7-yl)(phenyl)methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2)..  Bioorg Med Chem Lett,  18  (24): (6454-6457).  [PMID:18974001]
125. Zhang X, Tellew JE, Luo Z, Moorjani M, Lin E, Lanier MC, Chen Y, Williams JP, Saunders J, Lechner SM, Markison S, Joswig T, Petroski R, Piercey J, Kargo W, Malany S, Santos M, Gross RS, Wen J, Jalali K, O'Brien Z, Stotz CE, Crespo MI, Díaz JL, Slee DH..  (2008)  Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease..  J Med Chem,  51  (22): (7099-7110).  [PMID:18947224]
126. Havale SH, Pal M..  (2009)  Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes..  Bioorg Med Chem,  17  (5): (1783-1802).  [PMID:19217790]
127. Kraus JM, Verlinde CL, Karimi M, Lepesheva GI, Gelb MH, Buckner FS..  (2009)  Rational modification of a candidate cancer drug for use against Chagas disease..  J Med Chem,  52  (6): (1639-1647).  [PMID:19239254]
128. Hubbard RD, Bamaung NY, Fidanze SD, Erickson SA, Palazzo F, Wilsbacher JL, Zhang Q, Tucker LA, Hu X, Kovar P, Osterling DJ, Johnson EF, Bouska J, Wang J, Davidsen SK, Bell RL, Sheppard GS..  (2009)  Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases..  Bioorg Med Chem Lett,  19  (6): (1718-1721).  [PMID:19217287]
129. Vachal P, Fletcher JM, Fong TM, Huang CC, Lao J, Xiao JC, Shen CP, Strack AM, Shearman L, Stribling S, Chen RZ, Frassetto A, Tong X, Wang J, Ball RG, Tsou NN, Hickey GJ, Thompson DF, Faidley TD, Nicolich S, Achanfuo-Yeboah J, Hora DF, Hale JJ, Hagmann WK..  (2009)  1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity..  J Med Chem,  52  (8): (2550-2558).  [PMID:19320488]
130. Charrier N, Clarke B, Cutler L, Demont E, Dingwall C, Dunsdon R, Hawkins J, Howes C, Hubbard J, Hussain I, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G..  (2009)  Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics..  Bioorg Med Chem Lett,  19  (13): (3664-3668).  [PMID:19428244]
131. Rano TA, Sieber-McMaster E, Pelton PD, Yang M, Demarest KT, Kuo GH..  (2009)  Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform..  Bioorg Med Chem Lett,  19  (9): (2456-2460).  [PMID:19339179]
132. Ammirati MJ, Andrews KM, Boyer DD, Brodeur AM, Danley DE, Doran SD, Hulin B, Liu S, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soglia CB, Treadway JL, VanVolkenburg MA, Wilder DC, Piotrowski DW..  (2009)  (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor..  Bioorg Med Chem Lett,  19  (7): (1991-1995).  [PMID:19275964]
133. Lumeras W, Caturla F, Vidal L, Esteve C, Balagué C, Orellana A, Domínguez M, Roca R, Huerta JM, Godessart N, Vidal B..  (2009)  Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase..  J Med Chem,  52  (17): (5531-5545).  [PMID:19678708]
134. Li W, Li J, Wu Y, Rancati F, Vallese S, Raveglia L, Wu J, Hotchandani R, Fuller N, Cunningham K, Morgan P, Fish S, Krykbaev R, Xu X, Tam S, Goldman SJ, Abraham W, Williams C, Sypek J, Mansour TS..  (2009)  Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma..  J Med Chem,  52  (17): (5408-5419).  [PMID:19725580]
135. Hille UE, Hu Q, Vock C, Negri M, Bartels M, Müller-Vieira U, Lauterbach T, Hartmann RW..  (2009)  Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls..  Eur J Med Chem,  44  (7): (2765-2775).  [PMID:19211174]
136. Stearns BA, Baccei C, Bain G, Broadhead A, Clark RC, Coate H, Evans JF, Fagan P, Hutchinson JH, King C, Lee C, Lorrain DS, Prasit P, Prodanovich P, Santini A, Scott JM, Stock NS, Truong YP..  (2009)  Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis..  Bioorg Med Chem Lett,  19  (16): (4647-4651).  [PMID:19608418]
137. Pisani L, Muncipinto G, Miscioscia TF, Nicolotti O, Leonetti F, Catto M, Caccia C, Salvati P, Soto-Otero R, Mendez-Alvarez E, Passeleu C, Carotti A..  (2009)  Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor..  J Med Chem,  52  (21): (6685-6706).  [PMID:19810674]
138. Bey E, Marchais-Oberwinkler S, Negri M, Kruchten P, Oster A, Klein T, Spadaro A, Werth R, Frotscher M, Birk B, Hartmann RW..  (2009)  New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity..  J Med Chem,  52  (21): (6724-6743).  [PMID:19831396]
139. Blass BE, Fensome A, Trybulski E, Magolda R, Gardell SJ, Liu K, Samuel M, Feingold I, Huselton C, Jackson CM, Djandjighian L, Ho D, Hennan J, Janusz JM..  (2009)  Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia..  J Med Chem,  52  (21): (6531-6534).  [PMID:19888755]
140. Du W, Jewell JP, Lin LS, Colandrea VJ, Xiao JC, Lao J, Shen CP, Bateman TJ, Reddy VB, Ha SN, Shah SK, Fong TM, Hale JJ, Hagmann WK..  (2009)  Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists..  Bioorg Med Chem Lett,  19  (17): (5195-5199).  [PMID:19632830]
141. Ghirmai S, Azar MR, Cashman JR..  (2009)  Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation..  Bioorg Med Chem,  17  (18): (6671-6681).  [PMID:19683449]
142. Nagashima S, Hondo T, Nagata H, Ogiyama T, Maeda J, Hoshii H, Kontani T, Kuromitsu S, Ohga K, Orita M, Ohno K, Moritomo A, Shiozuka K, Furutani M, Takeuchi M, Ohta M, Tsukamoto S..  (2009)  Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors..  Bioorg Med Chem,  17  (19): (6926-6936).  [PMID:19747833]
143. Haydar SN, Yun H, Andrae PM, Mattes J, Zhang J, Kramer A, Smith DL, Huselton C, Graf R, Aschmies S, Schechter LE, Comery TA, Robichaud AJ..  (2010)  5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists..  J Med Chem,  53  (6): (2521-2527).  [PMID:20170099]
144. Ahmad S, Ngu K, Miller KJ, Wu G, Hung CP, Malmstrom S, Zhang G, O'Tanyi E, Keim WJ, Cullen MJ, Rohrbach KW, Thomas M, Ung T, Qu Q, Gan J, Narayanan R, Pelleymounter MA, Robl JA..  (2010)  Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents..  Bioorg Med Chem Lett,  20  (3): (1128-1133).  [PMID:20022752]
145. Sato T, Ashizawa N, Matsumoto K, Iwanaga T, Nakamura H, Inoue T, Nagata O..  (2009)  Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]..  Bioorg Med Chem Lett,  19  (21): (6225-6229).  [PMID:19783139]
146. Lu T, Markotan T, Ballentine SK, Giardino EC, Spurlino J, Crysler CS, Brown K, Maryanoff BE, Tomczuk BE, Damiano BP, Shukla U, End D, Andrade-Gordon P, Bone RF, Player MR..  (2010)  Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif..  J Med Chem,  53  (4): (1843-1856).  [PMID:20102150]
147. Chen A, Bayly C, Bezençon O, Richard-Bildstein S, Dubé D, Dubé L, Gagné S, Gallant M, Gaudreault M, Grimm E, Houle R, Lacombe P, Laliberté S, Lévesque JF, Liu S, MacDonald D, Mackay B, Martin D, McKay D, Powell D, Remen L, Soisson S, Toulmond S..  (2010)  Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension..  Bioorg Med Chem Lett,  20  (7): (2204-2209).  [PMID:20206513]
148. Pettus LH, Wurz RP, Xu S, Herberich B, Henkle B, Liu Q, McBride HJ, Mu S, Plant MH, Saris CJ, Sherman L, Wong LM, Chmait S, Lee MR, Mohr C, Hsieh F, Tasker AS..  (2010)  Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase..  J Med Chem,  53  (7): (2973-2985).  [PMID:20218619]
149. Li J, Kennedy LJ, Shi Y, Tao S, Ye XY, Chen SY, Wang Y, Hernández AS, Wang W, Devasthale PV, Chen S, Lai Z, Zhang H, Wu S, Smirk RA, Bolton SA, Ryono DE, Zhang H, Lim NK, Chen BC, Locke KT, O'Malley KM, Zhang L, Srivastava RA, Miao B, Meyers DS, Monshizadegan H, Search D, Grimm D, Zhang R, Harrity T, Kunselman LK, Cap M, Kadiyala P, Hosagrahara V, Zhang L, Xu C, Li YX, Muckelbauer JK, Chang C, An Y, Krystek SR, Blanar MA, Zahler R, Mukherjee R, Cheng PT, Tino JA..  (2010)  Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453)..  J Med Chem,  53  (7): (2854-2864).  [PMID:20218621]
150. Bursavich MG, Brooijmans N, Feldberg L, Hollander I, Kim S, Lombardi S, Park K, Mallon R, Gilbert AM..  (2010)  Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies..  Bioorg Med Chem Lett,  20  (8): (2586-2590).  [PMID:20303263]
151. Yan L, Huo P, Debenham JS, Madsen-Duggan CB, Lao J, Chen RZ, Xiao JC, Shen CP, Stribling DS, Shearman LP, Strack AM, Tsou N, Ball RG, Wang J, Tong X, Bateman TJ, Reddy VB, Fong TM, Hale JJ..  (2010)  Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity..  J Med Chem,  53  (10): (4028-4037).  [PMID:20423086]
152. Ray S, Madrid PB, Catz P, LeValley SE, Furniss MJ, Rausch LL, Guy RK, DeRisi JL, Iyer LV, Green CE, Mirsalis JC..  (2010)  Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models..  J Med Chem,  53  (9): (3685-3695).  [PMID:20361799]
153. Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, Faisal A, Urban F, Valenti M, de Haven Brandon A, Box G, Raynaud FI, Workman P, Eccles SA, Bayliss R, Blagg J, Linardopoulos S, McDonald E..  (2010)  Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate..  J Med Chem,  53  (14): (5213-5228).  [PMID:20565112]
154. Véniant MM, Hale C, Hungate RW, Gahm K, Emery MG, Jona J, Joseph S, Adams J, Hague A, Moniz G, Zhang J, Bartberger MD, Li V, Syed R, Jordan S, Komorowski R, Chen MM, Cupples R, Kim KW, St Jean DJ, Johansson L, Henriksson MA, Williams M, Vallgårda J, Fotsch C, Wang M..  (2010)  Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221)..  J Med Chem,  53  (11): (4481-4487).  [PMID:20465278]
155. Peddibhotla S, Shi R, Khan P, Smith LH, Mangravita-Novo A, Vicchiarelli M, Su Y, Okolotowicz KJ, Cashman JR, Reed JC, Roth GP..  (2010)  Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules..  J Med Chem,  53  (12): (4793-4797).  [PMID:20481485]
156. Hu Q, Yin L, Jagusch C, Hille UE, Hartmann RW..  (2010)  Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors..  J Med Chem,  53  (13): (5049-5053).  [PMID:20550118]
157. Clarke B, Cutler L, Demont E, Dingwall C, Dunsdon R, Hawkins J, Howes C, Hussain I, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G..  (2010)  BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296..  Bioorg Med Chem Lett,  20  (15): (4639-4644).  [PMID:20579874]
158. Brigance RP, Meng W, Fura A, Harrity T, Wang A, Zahler R, Kirby MS, Hamann LG..  (2010)  Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes..  Bioorg Med Chem Lett,  20  (15): (4395-4398).  [PMID:20598534]
159. Adams CM, Hu CW, Jeng AY, Karki R, Ksander G, Lasala D, Leung-Chu J, Liang G, Liu Q, Meredith E, Rao C, Rigel DF, Shi J, Smith S, Springer C, Zhang C..  (2010)  The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase..  Bioorg Med Chem Lett,  20  (15): (4324-4327).  [PMID:20615692]
160. Ward SE, Harries M, Aldegheri L, Andreotti D, Ballantine S, Bax BD, Harris AJ, Harker AJ, Lund J, Melarange R, Mingardi A, Mookherjee C, Mosley J, Neve M, Oliosi B, Profeta R, Smith KJ, Smith PW, Spada S, Thewlis KM, Yusaf SP..  (2010)  Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator..  J Med Chem,  53  (15): (5801-5812).  [PMID:20614889]
161. Arhancet GB, Woodard SS, Iyanar K, Case BL, Woerndle R, Dietz JD, Garland DJ, Collins JT, Payne MA, Blinn JR, Pomposiello SI, Hu X, Heron MI, Huang HC, Lee LF..  (2010)  Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists..  J Med Chem,  53  (16): (5970-5978).  [PMID:20672820]
162. Schlegel KA, Yang ZQ, Reger TS, Shu Y, Cube R, Rittle KE, Bondiskey P, Bock MG, Hartman GD, Tang C, Ballard J, Kuo Y, Prueksaritanont T, Nuss CE, Doran SM, Fox SV, Garson SL, Kraus RL, Li Y, Uebele VN, Renger JJ, Barrow JC..  (2010)  Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists..  Bioorg Med Chem Lett,  20  (17): (5147-5152).  [PMID:20673719]
163. Tipparaju SK, Muench SP, Mui EJ, Ruzheinikov SN, Lu JZ, Hutson SL, Kirisits MJ, Prigge ST, Roberts CW, Henriquez FL, Kozikowski AP, Rice DW, McLeod RL..  (2010)  Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase..  J Med Chem,  53  (17): (6287-6300).  [PMID:20698542]
164. Corminboeuf O, Bezençon O, Grisostomi C, Remeň L, Richard-Bildstein S, Bur D, Prade L, Hess P, Strickner P, Fischli W, Steiner B, Treiber A..  (2010)  Design and optimization of new piperidines as renin inhibitors..  Bioorg Med Chem Lett,  20  (21): (6286-6290).  [PMID:20843686]
165. Castanedo GM, Wang S, Robarge KD, Blackwood E, Burdick D, Chang C, Dijkgraaf GJ, Gould S, Gunzner J, Guichert O, Halladay J, Khojasteh C, Lee L, Marsters JC, Murray L, Peterson D, Plise E, Salphati L, de Sauvage FJ, Wong S, Sutherlin DP..  (2010)  Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway..  Bioorg Med Chem Lett,  20  (22): (6748-6753).  [PMID:20875741]
166. Webb RL, Schiering N, Sedrani R, Maibaum J..  (2010)  Direct renin inhibitors as a new therapy for hypertension..  J Med Chem,  53  (21): (7490-7520).  [PMID:20731374]
167. Gianotti M, Botta M, Brough S, Carletti R, Castiglioni E, Corti C, Dal-Cin M, Delle Fratte S, Korajac D, Lovric M, Merlo G, Mesic M, Pavone F, Piccoli L, Rast S, Roscic M, Sava A, Smehil M, Stasi L, Togninelli A, Wigglesworth MJ..  (2010)  Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders..  J Med Chem,  53  (21): (7778-7795).  [PMID:20942472]
168. Jeong S, Nguyen PD, Desta Z..  (2009)  Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A..  Antimicrob Agents Chemother,  53  (2): (541-551).  [PMID:19029318]
169. Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM..  (2011)  Potent and selective thiophene urea-templated inhibitors of S6K..  Bioorg Med Chem Lett,  21  (2): (849-852).  [PMID:21185721]
170. Gilbert AM, Bursavich MG, Lombardi S, Adedoyin A, Dwyer JM, Hughes Z, Kern JC, Khawaja X, Rosenzweig-Lipson S, Moore WJ, Neal SJ, Olsen M, Rizzo SJ, Springer D..  (2011)  3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies..  Bioorg Med Chem Lett,  21  (1): (195-199).  [PMID:21126874]
171. Richter HG, Benson GM, Blum D, Chaput E, Feng S, Gardes C, Grether U, Hartman P, Kuhn B, Martin RE, Plancher JM, Rudolph MG, Schuler F, Taylor S, Bleicher KH..  (2011)  Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes..  Bioorg Med Chem Lett,  21  (1): (191-194).  [PMID:21134747]
172. Manning DD, Cioffi CL, Usyatinsky A, Fitzpatrick K, Masih L, Guo C, Zhang Z, Choo SH, Sikkander MI, Ryan KN, Naginskaya J, Hassler C, Dobritsa S, Wierschke JD, Earley WG, Butler AS, Brady CA, Barnes NM, Cohen ML, Guzzo PR..  (2011)  Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome..  Bioorg Med Chem Lett,  21  (1): (58-61).  [PMID:21146988]
173. Barker RH, Liu H, Hirth B, Celatka CA, Fitzpatrick R, Xiang Y, Willert EK, Phillips MA, Kaiser M, Bacchi CJ, Rodriguez A, Yarlett N, Klinger JD, Sybertz E..  (2009)  Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis..  Antimicrob Agents Chemother,  53  (5): (2052-2058).  [PMID:19289530]
174. Zhang Z, Wallace MB, Feng J, Stafford JA, Skene RJ, Shi L, Lee B, Aertgeerts K, Jennings A, Xu R, Kassel DB, Kaldor SW, Navre M, Webb DR, Gwaltney SL..  (2011)  Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV..  J Med Chem,  54  (2): (510-524).  [PMID:21186796]
175. Marchais-Oberwinkler S, Wetzel M, Ziegler E, Kruchten P, Werth R, Henn C, Hartmann RW, Frotscher M..  (2011)  New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases..  J Med Chem,  54  (2): (534-547).  [PMID:21189020]
176. Stock N, Volkots D, Stebbins K, Broadhead A, Stearns B, Roppe J, Parr T, Baccei C, Bain G, Chapman C, Correa L, Darlington J, King C, Lee C, Lorrain DS, Prodanovich P, Santini A, Evans JF, Hutchinson JH, Prasit P..  (2011)  Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist..  Bioorg Med Chem Lett,  21  (3): (1036-1040).  [PMID:21211969]
177. Anandan SK, Webb HK, Chen D, Wang YX, Aavula BR, Cases S, Cheng Y, Do ZN, Mehra U, Tran V, Vincelette J, Waszczuk J, White K, Wong KR, Zhang LN, Jones PD, Hammock BD, Patel DV, Whitcomb R, MacIntyre DE, Sabry J, Gless R..  (2011)  1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia..  Bioorg Med Chem Lett,  21  (3): (983-988).  [PMID:21211973]
178. Tajima H, Honda T, Kawashima K, Sasabuchi Y, Yamamoto M, Ban M, Okamoto K, Inoue K, Inaba T, Takeno Y, Tsuboi T, Tonouchi A, Aono H..  (2011)  Pyridylmethylthio derivatives as VEGF inhibitors: part 2..  Bioorg Med Chem Lett,  21  (4): (1232-1235).  [PMID:21247763]
179. Engers DW, Field JR, Le U, Zhou Y, Bolinger JD, Zamorano R, Blobaum AL, Jones CK, Jadhav S, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR..  (2011)  Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats..  J Med Chem,  54  (4): (1106-1110).  [PMID:21247167]
180. Bass JY, Caravella JA, Chen L, Creech KL, Deaton DN, Madauss KP, Marr HB, McFadyen RB, Miller AB, Mills WY, Navas F, Parks DJ, Smalley TL, Spearing PK, Todd D, Williams SP, Wisely GB..  (2011)  Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene..  Bioorg Med Chem Lett,  21  (4): (1206-1213).  [PMID:21256005]
181. Patch RJ, Searle LL, Kim AJ, De D, Zhu X, Askari HB, O'Neill JC, Abad MC, Rentzeperis D, Liu J, Kemmerer M, Lin L, Kasturi J, Geisler JG, Lenhard JM, Player MR, Gaul MD..  (2011)  Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents..  J Med Chem,  54  (3): (788-808).  [PMID:21218783]
182. De Savi C, Pape A, Cumming JG, Ting A, Smith PD, Burrows JN, Mills M, Davies C, Lamont S, Milne D, Cook C, Moore P, Sawyer Y, Gerhardt S..  (2011)  The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis..  Bioorg Med Chem Lett,  21  (5): (1376-1381).  [PMID:21300546]
183. Shao L, Hewitt MC, Wang F, Malcolm SC, Ma J, Campbell JE, Campbell UC, Engel SR, Spicer NA, Hardy LW, Schreiber R, Spear KL, Varney MA..  (2011)  Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor..  Bioorg Med Chem Lett,  21  (5): (1438-1441).  [PMID:21310609]
184. Shao L, Hewitt MC, Wang F, Malcolm SC, Ma J, Campbell JE, Campbell UC, Engel SR, Spicer NA, Hardy LW, Schreiber R, Spear KL, Varney MA..  (2011)  Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor..  Bioorg Med Chem Lett,  21  (5): (1434-1437).  [PMID:21310612]
185. Andrews KM, Beebe DA, Benbow JW, Boyer DA, Doran SD, Hui Y, Liu S, McPherson RK, Neagu C, Parker JC, Piotrowski DW, Schneider SR, Treadway JL, VanVolkenberg MA, Zembrowski WJ..  (2011)  1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes..  Bioorg Med Chem Lett,  21  (6): (1810-1814).  [PMID:21324688]
186. Laborde E, Macsata RW, Meng F, Peterson BT, Robinson L, Schow SR, Simon RJ, Xu H, Baba K, Inagaki H, Ishiwata Y, Jomori T, Matsumoto Y, Miyachi A, Nakamura T, Okamoto M, Handel TM, Bernard CC..  (2011)  Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function..  J Med Chem,  54  (6): (1667-1681).  [PMID:21341682]
187. Lesuisse D, Mauger J, Nemecek C, Maignan S, Boiziau J, Harlow G, Hittinger A, Ruf S, Strobel H, Nair A, Ritter K, Malleron JL, Dagallier A, El-Ahmad Y, Guilloteau JP, Guizani H, Bouchard H, Venot C..  (2011)  Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors..  Bioorg Med Chem Lett,  21  (8): (2224-2228).  [PMID:21441024]
188. Xia G, Benmohamed R, Kim J, Arvanites AC, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB..  (2011)  Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis..  J Med Chem,  54  (7): (2409-2421).  [PMID:21375347]
189. Lucas S, Negri M, Heim R, Zimmer C, Hartmann RW..  (2011)  Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives..  J Med Chem,  54  (7): (2307-2319).  [PMID:21384875]
190. Qian Y, Wertheimer SJ, Ahmad M, Cheung AW, Firooznia F, Hamilton MM, Hayden S, Li S, Marcopulos N, McDermott L, Tan J, Yun W, Guo L, Pamidimukkala A, Chen Y, Huang KS, Ramsey GB, Whittard T, Conde-Knape K, Taub R, Rondinone CM, Tilley J, Bolin D..  (2011)  Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes..  J Med Chem,  54  (7): (2433-2446).  [PMID:21413799]
191. Shiozaki M, Maeda K, Miura T, Kotoku M, Yamasaki T, Matsuda I, Aoki K, Yasue K, Imai H, Ubukata M, Suma A, Yokota M, Hotta T, Tanaka M, Hase Y, Haas J, Fryer AM, Laird ER, Littmann NM, Andrews SW, Josey JA, Mimura T, Shinozaki Y, Yoshiuchi H, Inaba T..  (2011)  Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors..  J Med Chem,  54  (8): (2839-2863).  [PMID:21417219]
192. Zehnder L, Bennett M, Meng J, Huang B, Ninkovic S, Wang F, Braganza J, Tatlock J, Jewell T, Zhou JZ, Burke B, Wang J, Maegley K, Mehta PP, Yin MJ, Gajiwala KS, Hickey MJ, Yamazaki S, Smith E, Kang P, Sistla A, Dovalsantos E, Gehring MR, Kania R, Wythes M, Kung PP..  (2011)  Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide..  J Med Chem,  54  (9): (3368-3385).  [PMID:21438541]
193. Kim HJ, Kwak WY, Min JP, Lee JY, Yoon TH, Kim HD, Shin CY, Kim MK, Choi SH, Kim HS, Yang EK, Cheong YH, Chae YN, Park KJ, Jang JM, Choi SJ, Son MH, Kim SH, Yoo M, Lee BJ..  (2011)  Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes..  Bioorg Med Chem Lett,  21  (12): (3809-3812).  [PMID:21570283]
194. Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Choi HG, Waller DL, Sim T, Sabatini DM, Gray NS..  (2011)  Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability..  Bioorg Med Chem Lett,  21  (13): (4036-4040).  [PMID:21621413]
195. Chen A, Campeau LC, Cauchon E, Chefson A, Ducharme Y, Dubé D, Falgueyret JP, Fournier PA, Gagné S, Grimm E, Han Y, Houle R, Huang JQ, Lacombe P, Laliberté S, Lévesque JF, Liu S, MacDonald D, Mackay B, McKay D, Percival MD, Regan C, Regan H, St-Jacques R, Toulmond S..  (2011)  Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines..  Bioorg Med Chem Lett,  21  (13): (3970-3975).  [PMID:21621998]
196. Zapf CW, Bloom JD, Li Z, Dushin RG, Nittoli T, Otteng M, Nikitenko A, Golas JM, Liu H, Lucas J, Boschelli F, Vogan E, Olland A, Johnson M, Levin JI..  (2011)  Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model..  Bioorg Med Chem Lett,  21  (15): (4602-4607).  [PMID:21715165]
197. Hudkins RL, Raddatz R, Tao M, Mathiasen JR, Aimone LD, Becknell NC, Prouty CP, Knutsen LJ, Yazdanian M, Moachon G, Ator MA, Mallamo JP, Marino MJ, Bacon ER, Williams M..  (2011)  Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist..  J Med Chem,  54  (13): (4781-4792).  [PMID:21634396]
198. Yuan J, Simpson RD, Zhao W, Tice CM, Xu Z, Cacatian S, Jia L, Flaherty PT, Guo J, Ishchenko A, Wu Z, McKeever BM, Scott BB, Bukhtiyarov Y, Berbaum J, Panemangalore R, Bentley R, Doe CP, Harrison RK, McGeehan GM, Singh SB, Dillard LW, Baldwin JJ, Claremon DA..  (2011)  Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket..  Bioorg Med Chem Lett,  21  (16): (4836-4843).  [PMID:21741239]
199. Zhang L, Fan J, Chong JH, Cesena A, Tam BY, Gilson C, Boykin C, Wang D, Aivazian D, Marcotte D, Xiao G, Le Brazidec JY, Piao J, Lundgren K, Hong K, Vu K, Nguyen K, Gan LS, Silvian L, Ling L, Teng M, Reff M, Takeda N, Timple N, Wang Q, Morena R, Khan S, Zhao S, Li T, Lee WC, Taveras AG, Chao J..  (2011)  Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I)..  Bioorg Med Chem Lett,  21  (18): (5633-5637).  [PMID:21798738]
200. Christiansen E, Urban C, Grundmann M, Due-Hansen ME, Hagesaether E, Schmidt J, Pardo L, Ullrich S, Kostenis E, Kassack M, Ulven T..  (2011)  Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties..  J Med Chem,  54  (19): (6691-6703).  [PMID:21854074]
201. Packiarajan M, Marzabadi MR, Desai M, Lu Y, Noble SA, Wong WC, Jubian V, Chandrasena G, Wolinsky TD, Zhong H, Walker MW, Wiborg O, Andersen K..  (2011)  Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder..  Bioorg Med Chem Lett,  21  (18): (5436-5441).  [PMID:21782428]
202. Demont EH, Arpino S, Bit RA, Campbell CA, Deeks N, Desai S, Dowell SJ, Gaskin P, Gray JR, Harrison LA, Haynes A, Heightman TD, Holmes DS, Humphreys PG, Kumar U, Morse MA, Osborne GJ, Panchal T, Philpott KL, Taylor S, Watson R, Willis R, Witherington J..  (2011)  Discovery of a brain-penetrant S1P₃-sparing direct agonist of the S1P₁ and S1P₅ receptors efficacious at low oral dose..  J Med Chem,  54  (19): (6724-6733).  [PMID:21838322]
203. Sun X, Qiu J, Strong SA, Green LS, Wasley JW, Blonder JP, Colagiovanni DB, Mutka SC, Stout AM, Richards JP, Rosenthal GJ..  (2011)  Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities..  Bioorg Med Chem Lett,  21  (19): (5849-5853).  [PMID:21855338]
204. Annedi SC, Maddaford SP, Mladenova G, Ramnauth J, Rakhit S, Andrews JS, Lee DK, Zhang D, Porreca F, Bunton D, Christie L..  (2011)  Discovery of N-(3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl) thiophene-2-carboximidamide as a selective inhibitor of human neuronal nitric oxide synthase (nNOS) for the treatment of pain..  J Med Chem,  54  (20): (7408-7416).  [PMID:21923116]
205. Chen A, Cauchon E, Chefson A, Dolman S, Ducharme Y, Dubé D, Falgueyret JP, Fournier PA, Gagné S, Gallant M, Grimm E, Han Y, Houle R, Huang JQ, Hughes G, Jûteau H, Lacombe P, Lauzon S, Lévesque JF, Liu S, Macdonald D, Mackay B, McKay D, Percival MD, St-Jacques R, Toulmond S..  (2011)  Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines..  Bioorg Med Chem Lett,  21  (13): (3976-3981).  [PMID:21641209]
206. Lebois EP, Digby GJ, Sheffler DJ, Melancon BJ, Tarr JC, Cho HP, Miller NR, Morrison R, Bridges TM, Xiang Z, Daniels JS, Wood MR, Conn PJ, Lindsley CW..  (2011)  Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071..  Bioorg Med Chem Lett,  21  (21): (6451-6455).  [PMID:21930376]
207. Ramnauth J, Speed J, Maddaford SP, Dove P, Annedi SC, Renton P, Rakhit S, Andrews J, Silverman S, Mladenova G, Zinghini S, Nair S, Catalano C, Lee DK, De Felice M, Porreca F..  (2011)  Design, synthesis, and biological evaluation of 3,4-dihydroquinolin-2(1H)-one and 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors..  J Med Chem,  54  (15): (5562-5575).  [PMID:21699209]
208. Buzard D, Han S, Thoresen L, Moody J, Lopez L, Kawasaki A, Schrader T, Sage C, Gao Y, Edwards J, Barden J, Thatte J, Fu L, Solomon M, Liu L, Al-Shamma H, Gatlin J, Le M, Xing C, Espinola S, Jones RM..  (2011)  Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists..  Bioorg Med Chem Lett,  21  (19): (6013-6018).  [PMID:21852130]
209. Lumeras W, Vidal L, Vidal B, Balagué C, Orellana A, Maldonado M, Domínguez M, Segarra V, Caturla F..  (2011)  1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase..  J Med Chem,  54  (22): (7899-7910).  [PMID:21999461]
210. Chowdhury S, Sessions EH, Pocas JR, Grant W, Schröter T, Lin L, Ruiz C, Cameron MD, Schürer S, LoGrasso P, Bannister TD, Feng Y..  (2011)  Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I)..  Bioorg Med Chem Lett,  21  (23): (7107-7112).  [PMID:22004718]
211. Chen A, Aspiotis R, Campeau LC, Cauchon E, Chefson A, Ducharme Y, Falgueyret JP, Gagné S, Han Y, Houle R, Laliberté S, Larouche G, Lévesque JF, McKay D, Percival D..  (2011)  Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines..  Bioorg Med Chem Lett,  21  (24): (7399-7404).  [PMID:22071301]
212. McNulty J, Nair JJ, Vurgun N, Difrancesco BR, Brown CE, Tsoi B, Crankshaw DJ, Holloway AC..  (2012)  Discovery of a novel class of aldol-derived 1,2,3-triazoles: potent and selective inhibitors of human cytochrome P450 19A1 (aromatase)..  Bioorg Med Chem Lett,  22  (1): (718-722).  [PMID:22079757]
213. Sun H, Bessire AJ, Vaz A..  (2012)  Dirlotapide as a model substrate to refine structure-based drug design strategies on CYP3A4-catalyzed metabolism..  Bioorg Med Chem Lett,  22  (1): (371-376).  [PMID:22094027]
214. Cadieux JA, Zhang Z, Mattice M, Brownlie-Cutts A, Fu J, Ratkay LG, Kwan R, Thompson J, Sanghara J, Zhong J, Goldberg YP..  (2012)  Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1)..  Bioorg Med Chem Lett,  22  (1): (90-95).  [PMID:22154351]
215. De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S..  (2012)  Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2..  Bioorg Med Chem Lett,  22  (1): (271-277).  [PMID:22153941]
216. Ho GD, Yang SW, Smotryski J, Bercovici A, Nechuta T, Smith EM, McElroy W, Tan Z, Tulshian D, McKittrick B, Greenlee WJ, Hruza A, Xiao L, Rindgen D, Mullins D, Guzzi M, Zhang X, Bleickardt C, Hodgson R..  (2012)  The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia..  Bioorg Med Chem Lett,  22  (2): (1019-1022).  [PMID:22222034]
217. Brand S, Cleghorn LA, McElroy SP, Robinson DA, Smith VC, Hallyburton I, Harrison JR, Norcross NR, Spinks D, Bayliss T, Norval S, Stojanovski L, Torrie LS, Frearson JA, Brenk R, Fairlamb AH, Ferguson MA, Read KD, Wyatt PG, Gilbert IH..  (2012)  Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors..  J Med Chem,  55  (1): (140-152).  [PMID:22148754]
218. Sutton JM, Clark DE, Dunsdon SJ, Fenton G, Fillmore A, Harris NV, Higgs C, Hurley CA, Krintel SL, MacKenzie RE, Duttaroy A, Gangl E, Maniara W, Sedrani R, Namoto K, Ostermann N, Gerhartz B, Sirockin F, Trappe J, Hassiepen U, Baeschlin DK..  (2012)  Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes..  Bioorg Med Chem Lett,  22  (3): (1464-1468).  [PMID:22177783]
219. Song X, Li X, Ruiz CH, Yin Y, Feng Y, Kamenecka TM, Cameron MD..  (2012)  Imidazopyridines as selective CYP3A4 inhibitors..  Bioorg Med Chem Lett,  22  (4): (1611-1614).  [PMID:22264486]
220. Omori N, Kouyama N, Yukimasa A, Watanabe K, Yokota Y, Tanioka H, Nambu H, Yukioka H, Sato N, Tanaka Y, Sekiguchi K, Okuno T..  (2012)  Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist..  Bioorg Med Chem Lett,  22  (5): (2020-2023).  [PMID:22300657]
221. Lacombe P, Arbour M, Aspiotis R, Cauchon E, Chen A, Dubé D, Falgueyret JP, Fournier PA, Gallant M, Grimm E, Han Y, Juteau H, Liu S, Mellon C, Ramtohul Y, Simard D, St-Jacques R, Tsui GC..  (2012)  3,4-Diarylpiperidines as potent renin inhibitors..  Bioorg Med Chem Lett,  22  (5): (1953-1957).  [PMID:22325946]
222. Brocklehurst KJ, Broo A, Butlin RJ, Brown HS, Clarke DS, Davidsson Ö, Goldberg K, Groombridge SD, Kelly EE, Leach A, McKerrecher D, O'Donnell C, Poucher S, Schofield P, Scott JS, Teague J, Westgate L, Wood MJ..  (2011)  Discovery, optimisation and in vivo evaluation of novel GPR119 agonists..  Bioorg Med Chem Lett,  21  (24): (7310-7316).  [PMID:22061639]
223. Davies DJ, Crowe M, Lucas N, Quinn J, Miller DD, Pritchard S, Grose D, Bettini E, Calcinaghi N, Virginio C, Abberley L, Goldsmith P, Michel AD, Chessell IP, Kew JN, Miller ND, Gunthorpe MJ..  (2012)  A novel series of benzimidazole NR2B-selective NMDA receptor antagonists..  Bioorg Med Chem Lett,  22  (7): (2620-2623).  [PMID:22366657]
224. Shultz MD, Kirby CA, Stams T, Chin DN, Blank J, Charlat O, Cheng H, Cheung A, Cong F, Feng Y, Fortin PD, Hood T, Tyagi V, Xu M, Zhang B, Shao W..  (2012)  [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding..  J Med Chem,  55  (3): (1127-1136).  [PMID:22260203]
225. Sun H, Scott DO..  (2011)  Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design..  ACS Med Chem Lett,  2  (8): (638-643).  [PMID:21841964]
226. Wang F, Good JA, Rath O, Kaan HY, Sutcliffe OB, Mackay SP, Kozielski F..  (2012)  Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity..  J Med Chem,  55  (4): (1511-1525).  [PMID:22248262]
227. William AD, Lee AC, Poulsen A, Goh KC, Madan B, Hart S, Tan E, Wang H, Nagaraj H, Chen D, Lee CP, Sun ET, Jayaraman R, Pasha MK, Ethirajulu K, Wood JM, Dymock BW..  (2012)  Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis..  J Med Chem,  55  (6): (2623-2640).  [PMID:22339472]
228. Stec J, Huang Q, Pieroni M, Kaiser M, Fomovska A, Mui E, Witola WH, Bettis S, McLeod R, Brun R, Kozikowski AP..  (2012)  Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania..  J Med Chem,  55  (7): (3088-3100).  [PMID:22352841]
229. McCoull W, Addie MS, Birch AM, Birtles S, Buckett LK, Butlin RJ, Bowker SS, Boyd S, Chapman S, Davies RD, Donald CS, Green CP, Jenner C, Kemmitt PD, Leach AG, Moody GC, Gutierrez PM, Newcombe NJ, Nowak T, Packer MJ, Plowright AT, Revill J, Schofield P, Sheldon C, Stokes S, Turnbull AV, Wang SJ, Whalley DP, Wood JM..  (2012)  Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes..  Bioorg Med Chem Lett,  22  (12): (3873-3878).  [PMID:22608962]
230. Seo BI, Uchil VR, Okello M, Mishra S, Ma XH, Nishonov M, Shu Q, Chi G, Nair V..  (2011)  Discovery of a Potent HIV Integrase Inhibitor that Leads to a Prodrug with Significant anti-HIV Activity..  ACS Med Chem Lett,  2  (12): (877-881).  [PMID:22328963]
231. Lai MJ, Huang HL, Pan SL, Liu YM, Peng CY, Lee HY, Yeh TK, Huang PH, Teng CM, Chen CS, Chuang HY, Liou JP..  (2012)  Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo..  J Med Chem,  55  (8): (3777-3791).  [PMID:22439863]
232. Buzard DJ, Han S, Lopez L, Kawasaki A, Moody J, Thoresen L, Ullman B, Lehmann J, Calderon I, Zhu X, Gharbaoui T, Sengupta D, Krishnan A, Gao Y, Edwards J, Barden J, Morgan M, Usmani K, Chen C, Sadeque A, Thatte J, Solomon M, Fu L, Whelan K, Liu L, Al-Shamma H, Gatlin J, Le M, Xing C, Espinola S, Jones RM..  (2012)  Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease..  Bioorg Med Chem Lett,  22  (13): (4404-4409).  [PMID:22633692]
233. Ohtake Y, Sato T, Matsuoka H, Kobayashi T, Nishimoto M, Taka N, Takano K, Yamamoto K, Ohmori M, Higuchi T, Murakata M, Morikawa K, Shimma N, Suzuki M, Hagita H, Ozawa K, Yamaguchi K, Kato M, Ikeda S..  (2012)  C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes..  Bioorg Med Chem,  20  (13): (4117-4127).  [PMID:22652255]
234. Zhang H, Zhou L, Amblard F, Shi J, Bobeck DR, Tao S, McBrayer TR, Tharnish PM, Whitaker T, Coats SJ, Schinazi RF..  (2012)  Synthesis and evaluation of novel potent HCV NS5A inhibitors..  Bioorg Med Chem Lett,  22  (14): (4864-4868).  [PMID:22704887]
235. Delpire E, Baranczak A, Waterson AG, Kim K, Kett N, Morrison RD, Daniels JS, Weaver CD, Lindsley CW..  (2012)  Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe..  Bioorg Med Chem Lett,  22  (14): (4532-4535).  [PMID:22727639]
236. Han X, Civiello RL, Conway CM, Cook DA, Davis CD, Macci R, Pin SS, Ren SX, Schartman R, Signor LJ, Thalody G, Widmann KA, Xu C, Chaturvedula PV, Macor JE, Dubowchik GM..  (2012)  The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1..  Bioorg Med Chem Lett,  22  (14): (4723-4727).  [PMID:22727645]
237. Martínez González S, Hernández AI, Varela C, Lorenzo M, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán MI, Alfonso P, García-Serelde B, Mateos G, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Blanco-Aparicio C, Pastor J..  (2012)  Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR..  Bioorg Med Chem Lett,  22  (16): (5208-5214).  [PMID:22819764]
238. Rai G, Vyjayanti VN, Dorjsuren D, Simeonov A, Jadhav A, Wilson DM, Maloney DJ..  (2012)  Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors..  J Med Chem,  55  (7): (3101-3112).  [PMID:22455312]
239. Nagle A, Wu T, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z, Plouffe D, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li C, Liu B, Hollenbeck T, Tuntland T, Isbell J, Chuan T, Alper PB, Fischli C, Brun R, Lakshminarayana SB, Rottmann M, Diagana TT, Winzeler EA, Glynne R, Tully DC, Chatterjee AK..  (2012)  Imidazolopiperazines: lead optimization of the second-generation antimalarial agents..  J Med Chem,  55  (9): (4244-4273).  [PMID:22524250]
240. Kim HJ, Kwak WY, Min JP, Sung SY, Kim HD, Kim MK, Kim HS, Park KJ, Son MH, Kim SH, Lee BJ..  (2012)  Dipeptidyl peptidase-4 inhibitor with β-amino amide scaffold: synthesis, SAR and biological evaluation..  Bioorg Med Chem Lett,  22  (17): (5545-5549).  [PMID:22850208]
241. Miyata J, Kasahara C, Asano T, Ito S, Seki N, Kato Y, Morikawa N, Nozaki K, Nishimura K, Akamatsu H, Taguchi Y, Yamaguchi T, Abe Y, Ohkubo M, Watanabe T, Ohta M, Takeuchi M..  (2012)  Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors..  Bioorg Med Chem Lett,  22  (17): (5681-5684).  [PMID:22853997]
242. Tamura Y, Omori N, Kouyama N, Nishiura Y, Hayashi K, Watanabe K, Tanaka Y, Chiba T, Yukioka H, Sato H, Okuno T..  (2012)  Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles..  Bioorg Med Chem Lett,  22  (17): (5498-5502).  [PMID:22853998]
243. Lizarzaburu M, Turcotte S, Du X, Duquette J, Fu A, Houze J, Li L, Liu J, Murakoshi M, Oda K, Okuyama R, Nara F, Reagan J, Yu M, Medina JC..  (2012)  Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus..  Bioorg Med Chem Lett,  22  (18): (5942-5947).  [PMID:22884988]
244. N'gompaza-Diarra J, Bettayeb K, Gresh N, Meijer L, Oumata N..  (2012)  Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors..  Eur J Med Chem,  56  (210-216).  [PMID:22982525]
245. Martínez González S, Hernández AI, Varela C, Rodríguez-Arístegui S, Lorenzo M, Rodríguez A, Rivero V, Martín JI, Saluste CG, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán M, Alfonso P, García-Serelde B, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Pastor J..  (2012)  Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor..  Bioorg Med Chem Lett,  22  (10): (3460-3466).  [PMID:22520259]
246. Ikuma Y, Hochigai H, Kimura H, Nunami N, Kobayashi T, Uchiyama K, Furuta Y, Sakai M, Horiguchi M, Masui Y, Okazaki K, Sato Y, Nakahira H..  (2012)  Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors..  Bioorg Med Chem,  20  (19): (5864-5883).  [PMID:22938786]
247. Bungard CJ, Hartman GD, Manikowski JJ, Perkins JJ, Bai C, Brandish PE, Euler DH, Hershey JC, Schmidt A, Fang Y, Norcross RT, Rushmore TH, Thompson CD, Meissner RS..  (2011)  Discovery of selective glucocorticoid receptor modulator MK-5932..  Bioorg Med Chem,  19  (24): (7374-7386).  [PMID:22079253]
248. Nakano H, Saito N, Parker L, Tada Y, Abe M, Tsuganezawa K, Yokoyama S, Tanaka A, Kojima H, Okabe T, Nagano T..  (2012)  Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound..  J Med Chem,  55  (11): (5151-5164).  [PMID:22540945]
249. Suzuki T, Khan MN, Sawada H, Imai E, Itoh Y, Yamatsuta K, Tokuda N, Takeuchi J, Seko T, Nakagawa H, Miyata N..  (2012)  Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors..  J Med Chem,  55  (12): (5760-5773).  [PMID:22642300]
250. Certal V, Halley F, Virone-Oddos A, Thompson F, Filoche-Rommé B, El-Ahmad Y, Carry JC, Delorme C, Karlsson A, Abecassis PY, Vincent L, Bonnevaux H, Nicolas JP, Morales R, Michot N, Vade I, Louboutin A, Perron S, Doerflinger G, Tric B, Monget S, Lengauer C, Schio L..  (2012)  Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors..  Bioorg Med Chem Lett,  22  (20): (6381-6384).  [PMID:22981333]
251. Leahy JW, Buhr CA, Johnson HW, Kim BG, Baik T, Cannoy J, Forsyth TP, Jeong JW, Lee MS, Ma S, Noson K, Wang L, Williams M, Nuss JM, Brooks E, Foster P, Goon L, Heald N, Holst C, Jaeger C, Lam S, Lougheed J, Nguyen L, Plonowski A, Song J, Stout T, Wu X, Yakes MF, Yu P, Zhang W, Lamb P, Raeber O..  (2012)  Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors..  J Med Chem,  55  (11): (5467-5482).  [PMID:22548342]
252. Illig CR, Manthey CL, Wall MJ, Meegalla SK, Chen J, Wilson KJ, Ballentine SK, Desjarlais RL, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE..  (2011)  Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)..  J Med Chem,  54  (22): (7860-7883).  [PMID:22039836]
253. Scott JS, Gill AL, Godfrey L, Groombridge SD, Rees A, Revill J, Schofield P, Sörme P, Stocker A, Swales JG, Whittamore PR..  (2012)  Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors..  Bioorg Med Chem Lett,  22  (21): (6756-6761).  [PMID:23013933]
254. Su X, Halem HA, Thomas MP, Moutrille C, Culler MD, Vicker N, Potter BV..  (2012)  Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors..  Bioorg Med Chem,  20  (21): (6394-6402).  [PMID:23040895]
255. Yu LF, Tückmantel W, Eaton JB, Caldarone B, Fedolak A, Hanania T, Brunner D, Lukas RJ, Kozikowski AP..  (2012)  Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity..  J Med Chem,  55  (2): (812-823).  [PMID:22148173]
256. Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB..  (2012)  ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis..  J Med Chem,  55  (1): (515-527).  [PMID:22191331]
257. Yu W, Gill T, Wang L, Du Y, Ye H, Qu X, Guo JT, Cuconati A, Zhao K, Block TM, Xu X, Chang J..  (2012)  Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection..  J Med Chem,  55  (13): (6061-6075).  [PMID:22712544]
258. Cheung YY, Yu H, Xu K, Zou B, Wu M, McManus OB, Li M, Lindsley CW, Hopkins CR..  (2012)  Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor..  J Med Chem,  55  (15): (6975-6979).  [PMID:22793372]
259. Sarabu R, Bizzarro FT, Corbett WL, Dvorozniak MT, Geng W, Grippo JF, Haynes NE, Hutchings S, Garofalo L, Guertin KR, Hilliard DW, Kabat M, Kester RF, Ka W, Liang Z, Mahaney PE, Marcus L, Matschinsky FM, Moore D, Racha J, Radinov R, Ren Y, Qi L, Pignatello M, Spence CL, Steele T, Tengi J, Grimsby J..  (2012)  Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients..  J Med Chem,  55  (16): (7021-7036).  [PMID:22809456]
260. Hu Q, Yin L, Hartmann RW..  (2012)  Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer..  J Med Chem,  55  (16): (7080-7089).  [PMID:22861193]
261. Huber JD, Bentzien J, Boyer SJ, Burke J, De Lombaert S, Eickmeier C, Guo X, Haist JV, Hickey ER, Kaplita P, Karmazyn M, Kemper R, Kennedy CA, Kirrane T, Madwed JB, Mainolfi E, Nagaraja N, Soleymanzadeh F, Swinamer A, Eldrup AB..  (2012)  Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat..  J Med Chem,  55  (16): (7114-7140).  [PMID:22803959]
262. Gonzalez-Lopez de Turiso F, Shin Y, Brown M, Cardozo M, Chen Y, Fong D, Hao X, He X, Henne K, Hu YL, Johnson MG, Kohn T, Lohman J, McBride HJ, McGee LR, Medina JC, Metz D, Miner K, Mohn D, Pattaropong V, Seganish J, Simard JL, Wannberg S, Whittington DA, Yu G, Cushing TD..  (2012)  Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors..  J Med Chem,  55  (17): (7667-7685).  [PMID:22876881]
263. Asano T, Yamazaki H, Kasahara C, Kubota H, Kontani T, Harayama Y, Ohno K, Mizuhara H, Yokomoto M, Misumi K, Kinoshita T, Ohta M, Takeuchi M..  (2012)  Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor..  J Med Chem,  55  (17): (7772-7785).  [PMID:22905713]
264. Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND..  (2012)  Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence..  J Med Chem,  55  (22): (9434-9445).  [PMID:23009245]
265. Wong JC, Tang G, Wu X, Liang C, Zhang Z, Guo L, Peng Z, Zhang W, Lin X, Wang Z, Mei J, Chen J, Pan S, Zhang N, Liu Y, Zhou M, Feng L, Zhao W, Li S, Zhang C, Zhang M, Rong Y, Jin TG, Zhang X, Ren S, Ji Y, Zhao R, She J, Ren Y, Xu C, Chen D, Cai J, Shan S, Pan D, Ning Z, Lu X, Chen T, He Y, Chen L..  (2012)  Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response..  J Med Chem,  55  (20): (8903-8925).  [PMID:23061376]
266. Kaila N, Huang A, Moretto A, Follows B, Janz K, Lowe M, Thomason J, Mansour TS, Hubeau C, Page K, Morgan P, Fish S, Xu X, Williams C, Saiah E..  (2012)  Diazine indole acetic acids as potent, selective, and orally bioavailable antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases..  J Med Chem,  55  (11): (5088-5109).  [PMID:22651823]
267. Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N..  (2012)  Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease..  Bioorg Med Chem Lett,  22  (14): (4613-4618).  [PMID:22726925]
268. Gomaa MS, Bridgens CE, Illingworth NA, Veal GJ, Redfern CP, Brancale A, Armstrong JL, Simons C..  (2012)  Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold..  Bioorg Med Chem,  20  (14): (4201-4207).  [PMID:22727372]
269. Liu X, Chan CB, Qi Q, Xiao G, Luo HR, He X, Ye K..  (2012)  Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression..  J Med Chem,  55  (19): (8524-8537).  [PMID:22984948]
270. Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M, Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A, Raynaud FI, Workman P, Eccles SA, Bayliss R, Linardopoulos S, Blagg J..  (2012)  Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia..  J Med Chem,  55  (20): (8721-8734).  [PMID:23043539]
271. Smethurst CA, Bevan N, Brooks C, Emmons A, Gough PJ, Mookherjee C, Moores K, Peace S, Philp J, Piercy V, Watson SP, Zippoli M..  (2012)  In vivo activity of an azole series of CCR2 antagonists..  Bioorg Med Chem Lett,  22  (23): (7252-7255).  [PMID:23079519]
272. Dickmann LJ, VandenBrink BM, Lin YS..  (2012)  In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties..  Drug Metab Dispos,  40  (7): (1263-1267).  [PMID:22531045]
273. Fredenhagen A, Kittelmann M, Oberer L, Kuhn A, Kühnöl J, Délémonté T, Aichholz R, Wang P, Atadja P, Shultz MD..  (2012)  Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589)..  Drug Metab Dispos,  40  (5): (1041-1050).  [PMID:22344701]
274. Xu L, Woodward C, Khan S, Prakash C..  (2012)  In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human cytochrome P450 isoforms..  Drug Metab Dispos,  40  (4): (680-693).  [PMID:22217465]
275. Foti RS, Rock DA, Pearson JT, Wahlstrom JL, Wienkers LC..  (2011)  Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction..  Drug Metab Dispos,  39  (7): (1188-1195).  [PMID:21447734]
276. Chan EC, New LS, Chua TB, Yap CW, Ho HK, Nelson SD..  (2012)  Interaction of lapatinib with cytochrome P450 3A5..  Drug Metab Dispos,  40  (7): (1414-1422).  [PMID:22511346]
277. Strelevitz TJ, Orozco CC, Obach RS..  (2012)  Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance..  Drug Metab Dispos,  40  (7): (1441-1448).  [PMID:22522748]
278. Kamdem LK, Flockhart DA, Desta Z..  (2011)  In vitro cytochrome P450-mediated metabolism of exemestane..  Drug Metab Dispos,  39  (1): (98-105).  [PMID:20876785]
279. Jin Y, Zollinger M, Borell H, Zimmerlin A, Patten CJ..  (2011)  CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis..  Drug Metab Dispos,  39  (2): (191-198).  [PMID:21045201]
280. Uchihashi S, Fukumoto H, Onoda M, Hayakawa H, Ikushiro S, Sakaki T..  (2011)  Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms..  Drug Metab Dispos,  39  (5): (803-813).  [PMID:21346002]
281. Walsky RL, Obach RS, Hyland R, Kang P, Zhou S, West M, Geoghegan KF, Helal CJ, Walker GS, Goosen TC, Zientek MA..  (2012)  Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs..  Drug Metab Dispos,  40  (9): (1686-1697).  [PMID:22645092]
282. Su H, Boulton DW, Barros A, Wang L, Cao K, Bonacorsi SJ, Iyer RA, Humphreys WG, Christopher LJ..  (2012)  Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human..  Drug Metab Dispos,  40  (7): (1345-1356).  [PMID:22496391]
283. Henne KR, Tran TB, VandenBrink BM, Rock DA, Aidasani DK, Subramanian R, Mason AK, Stresser DM, Teffera Y, Wong SG, Johnson MG, Chen X, Tonn GR, Wong BK..  (2012)  Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme..  Drug Metab Dispos,  40  (7): (1429-1440).  [PMID:22517972]
284. Bakken GV, Molden E, Knutsen K, Lunder N, Hermann M..  (2012)  Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro..  Drug Metab Dispos,  40  (9): (1778-1784).  [PMID:22688609]
285. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jørgensen M, Püschl A, Dalgaard L..  (2012)  Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004..  Drug Metab Dispos,  40  (7): (1357-1365).  [PMID:22496396]
286. Bork, R W RW and 5 more authors..  (1989)  Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity..  The Journal of biological chemistry,    (15):   [PMID:2463251]
287. Aoyama, T T and 9 more authors..  (1989)  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine..  The Journal of biological chemistry,    (25):   [PMID:2732228]
288. Komori, M M and 6 more authors..  (1988)  Cytochrome P-450 in human liver microsomes: high-performance liquid chromatographic isolation of three forms and their characterization..  Journal of biochemistry,      [PMID:3243766]
289. Gonzalez, F J FJ and 7 more authors..  (1988)  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase..  DNA (Mary Ann Liebert, Inc.),      [PMID:3267210]
290. Molowa, D T DT and 7 more authors..  (1986)  Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver..  Proceedings of the National Academy of Sciences of the United States of America,      [PMID:3460094]
291. Beaune, P H PH, Umbenhauer, D R DR, Bork, R W RW, Lloyd, R S RS and Guengerich, F P FP..  (1986)  Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase..  Proceedings of the National Academy of Sciences of the United States of America,      [PMID:3464943]
292. Watkins, P B PB and 6 more authors..  (1985)  Identification of an inducible form of cytochrome P-450 in human liver..  Proceedings of the National Academy of Sciences of the United States of America,      [PMID:3898085]
293. Kolars, J C JC and 7 more authors..  (1994)  CYP3A gene expression in human gut epithelium..  Pharmacogenetics,      [PMID:7894497]
294. Chen, Q Q, Wu, J J and Yu, Y Y..  (1998)  [Establishment of transgenic cell line CHL-3A4 and its metabolic activation]..  Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine],      [PMID:10322772]
295. Sata, F F and 8 more authors..  (2000)  CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity..  Clinical pharmacology and therapeutics,      [PMID:10668853]
296. Marill, J J, Cresteil, T T, Lanotte, M M and Chabot, G G GG..  (2000)  Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites..  Molecular pharmacology,      [PMID:11093772]
297. Hsieh, K P KP and 6 more authors..  (2001)  Novel mutations of CYP3A4 in Chinese..  Drug metabolism and disposition: the biological fate of chemicals,      [PMID:11181494]
298. Gellner, K K and 16 more authors..  (2001)  Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene..  Pharmacogenetics,      [PMID:11266076]
299. Eiselt, R R and 13 more authors..  (2001)  Identification and functional characterization of eight CYP3A4 protein variants..  Pharmacogenetics,      [PMID:11470997]
300. Badawi, A F AF, Cavalieri, E L EL and Rogan, E G EG..  (2001)  Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol..  Metabolism: clinical and experimental,      [PMID:11555828]
301. Dai, D D and 6 more authors..  (2001)  Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos..  The Journal of pharmacology and experimental therapeutics,      [PMID:11714865]
302. Finta, Csaba C and Zaphiropoulos, Peter G PG..  (2002)  Intergenic mRNA molecules resulting from trans-splicing..  The Journal of biological chemistry,    (22):   [PMID:11726664]
303. Lamba, Jatinder K JK and 7 more authors..  (2002)  Common allelic variants of cytochrome P4503A4 and their prevalence in different populations..  Pharmacogenetics,      [PMID:11875366]
304. Lee, Anthony J AJ, Conney, Allan H AH and Zhu, Bao Ting BT..  (2003)  Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16alpha-hydroxylation of estrone but not 17beta-estradiol..  Cancer research,    (1):   [PMID:14559847]
305. Yano, Jason K JK and 5 more authors..  (2004)  The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution..  The Journal of biological chemistry,    (10):   [PMID:15258162]
306. Solus, Joseph F JF and 9 more authors..  (2004)  Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population..  Pharmacogenomics,      [PMID:15469410]
307. Pabarcus, Michael K MK and 5 more authors..  (2009)  CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases..  Archives of biochemistry and biophysics,    (1):   [PMID:19103148]
308. Badal, Simone; Gallimore, Winklet; Huang, George; Tzeng, Tzuen-Rong Jeremy and Delgoda, Rupika..  (2012)  Cytotoxic and potent CYP1 inhibitors from the marine algae Cymopolia barbata..  Organic and medicinal chemistry letters,    (11):   [PMID:22686946]
309. Cheng, Qian Q, Sohl, Christal D CD, Yoshimoto, Francis K FK and Guengerich, F Peter FP..  (2012)  Oxidation of dihydrotestosterone by human cytochromes P450 19A1 and 3A4..  The Journal of biological chemistry,    (24):   [PMID:22773874]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.